Somatic mutations in ageing and disease

Somatic mutations in ageing and disease

Title history
  • Somatic mutations in ageing and disease — observed on 20261026-2036 UTC (YouTube)
🎙 Peter Campbell (Wellcome Sanger Institute, UK) 👥 16K 📅 July 22, 2022 ⏱ 43 min 👁 1K 📄 original study 🧭 2026-10-26
Available in: English (current) Français

Keywords

somatic mutationsageingclonal haematopoiesisFOXO1positive selection

Summary

Peter Campbell delivers a keynote talk on somatic mutations in ageing and disease, presenting original research from his Wellcome Sanger Institute group. He frames the work by noting that cancer genome sequencing only reveals clonal structure emerging shortly before diagnosis, whereas sequencing normal tissues can characterise the preceding mutational landscape. Across all tissues studied, somatic mutation burden increases linearly with age, with tissue-specific rates (15-20 mutations per cell per year in blood, 40-50 in colon). The first study examined haematopoietic stem cells: 3,500 whole genomes from single-cell-derived colonies of 10 individuals. Young individuals show highly polyclonal haematopoiesis, but after age 70, haematopoiesis becomes oligo-clonal, with 30-60% of blood cells deriving from 10-20 independent clones. Most expanded clones lack known driver mutations, and analysis of synonymous versus non-synonymous mutations shows about 1 in 15-20 non-synonymous mutations is under positive selection. Approximate Bayesian computation simulations with a constant driver mutation rate reproduce the observed sharp decline in clonal diversity after age 70, suggesting this is a universal feature of ageing. The second study examined chronic liver disease, sequencing 1,590 genomes from 34 patients. Recurrent hotspot mutations appeared in FOXO1 (serine-to-tryptophan at position 22), CIDEB and GPAM, with remarkable convergent evolution (up to nine independent FOXO1 clones in a single patient). FOXO1 mutations render hepatocytes insulin-resistant, shown through in vitro assays and metabolic profile. These mutations are largely absent from normal liver and hepatocellular carcinoma, indicating disease-specific selective advantages.

236 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of the information is exceptionally high, presenting original research that fundamentally advances understanding of somatic mutation and selection in normal tissues. The data are substantial (3,500 whole genomes from blood colonies and 1,590 from liver), with rigorous quality controls and clear phylogenetic inference. Argumentation is solid and multi-layered: the presenter establishes a quantitative framework by using synonymous mutations as a neutral baseline to estimate driver mutation rates, and then validates the inferred rates through independent Bayesian simulation. The logical chain from observation (clonal expansions without known drivers) to hypothesis (unidentified drivers or neutral selection) to resolution (genetic test showing positive selection) is well constructed and convincing. The presenter is appropriately cautious, acknowledging that some expanded clones may have unidentified driver mutations. A notable strength is the demonstration of specificity: FOXO1 and CIDEB mutations are enriched in chronic liver disease but absent from normal liver and hepatocellular carcinoma, which strongly supports their disease-context-specific selective advantage rather than generic cancer-promoting effects. The convergent evolution observations are particularly persuasive, as identical mutations arising independently multiple times within the same patient cannot reasonably be attributed to chance.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigour is excellent: the presentation rests on large-scale genomic datasets, appropriate statistical genetics methods (including dN/dS analysis via synonymous mutations as neutral reference), and simulation-based inference. The presenter references his own published work and mentions related presentations from the same conference (e.g., brain and heart mutation studies), but no external literature is cited with specific references or URLs, and the video description contains no links beyond the presenter affiliation. The strength of the evidence rests on the data and methods described, which are consistent with established practices in the field. The title is well matched to the content, accurately summarising the focus on somatic mutations in the contexts of ageing and disease. No public comments were available for analysis.

321 words

Title / Content Match

The title accurately reflects the content: the talk covers somatic mutations in ageing (mutation burden increase, clonal diversity decline) and in disease (chronic liver disease, cancer risk).

Quality & Reliability

9/10

Keynote presentation by a leading cancer genomics researcher, presenting original peer-reviewed research based on large datasets (3,500 haematopoietic stem cell genomes and 1,590 liver genomes). Rigorous methodology including phylogenetic reconstruction, dN/dS-type neutral baseline analysis, and Bayesian simulation. Claims are appropriately cautious, with clear distinction between observation and inference. Strong quantitative support for conclusions.

Key Moments

Contribution & Novelties

The presentation provides two significant original contributions. First, it demonstrates that the decline in clonal diversity of haematopoiesis after age 70 is a quantitative consequence of a constant mutation rate and constant driver fraction, making it a universal mathematical feature of ageing rather than a stochastic accident. Second, it identifies a novel class of disease-context-specific driver mutations in chronic liver disease: FOXO1, CIDEB and GPAM mutations confer selective advantages specific to the disease state (insulin resistance, altered lipid droplet handling), are absent from normal liver and hepatocellular carcinoma, and show striking convergent evolution. This challenges the view that positive selection in normal tissues is primarily a stepping stone to cancer, proposing instead a richer landscape of selection with implications for organ dysfunction and disease.

Pour aller plus loin :

195 words

Radar Profile

The radar profile is dense on all four axes, with quantification of information and reliability being the most prominent. The technical level is high, reflecting an advanced genomics methodology, while the quality of information remains consistently strong given the large datasets and rigorous analysis.

Reliability 9/10